The latest announcement is out from Xlife Sciences Ltd. ( (CH:XLS) ).
Xlife Sciences AG has released its Valuation Report 2024, confirming sustainable value development and strategic scaling of its portfolio. The report, conducted by CYLAD Consulting, evaluates 16 project companies and estimates the portfolio value between CHF 617.4 million and CHF 754.7 million. The report highlights the significant potential of Xlife Sciences’ portfolio, with the largest share in technology platforms and biotechnology/therapies. The company is exploring a possible IPO for FUSE-AI GmbH to achieve broader market entry and access growth capital, indicating a strategic move towards international expansion and increased shareholder value.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss company that serves as an incubator and accelerator, focusing on the development and commercialization of promising research projects from universities and research institutions in the life sciences sector. The company aims to address high unmet medical needs and improve quality of life by advancing projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
YTD Price Performance: -23.23%
Average Trading Volume: 4,358
Current Market Cap: CHF112M
Learn more about XLS stock on TipRanks’ Stock Analysis page.